Prescription RequiredErdafitinib is an oral targeted cancer medicine used for selected advanced or metastatic urothelial cancers with susceptible FGFR genetic alterations. Genetic testing is required to determine eligibility, and treatment must be managed by an experienced oncologist.
| Generic Name | Erdafitinib |
| Strength | 4 mg |
| Manufacturer | Natco |
| Packing | 28 Tablets |
| Prescribed For | Treat adults with advanced or spreading bladder cancer (urothelial carcinoma) |
| Availability | In Stock |
| Shipping to | USA, UK, Australia, Canada, New Zealand, Philippines, Tunisia, France, Italy, South Korea, Albania, Romania, Hong Kong, Malaysia, Thailand, Singapore, Japan, UAE, Saudi Arabia, Qatar, Kuwait, Georgia, Mexico, and many other countries. |
| Package | USD | GBP | AUD | NZD | PHP | KRW | RON | HKD | MYR | THB | AED |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 28 Tablets | $390 | £290 | A$547 | NZ$680 | ₱24,418 | ₩526,305 | lei 1,777 | HK$3,058 | RM1,588 | ฿12,741 | د.إ1,432 |
Erdafitinib blocks fibroblast growth factor receptors, particularly abnormal FGFR activity in certain cancer cells. These receptors can continuously send signals that promote uncontrolled cell growth. Blocking them slows the growth and spread of FGFR-altered tumours.
Erdafitinib prices may vary between countries depending on the brand, strength, pack size, pharmacy, insurance coverage, government subsidies, taxes and local healthcare policies. The following resources provide country-specific pricing, reimbursement, regulatory or medicine information.
Disclaimer
This website operates in compliance with applicable pharmaceutical laws. All content and data available on this website are intended solely for informational purposes. The information provided is not a substitute for professional medical advice, diagnosis, or treatment. Information provided here is for general awareness and does not replace medical advice. We strongly encourage you to consult a qualified healthcare professional for guidance.
